These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32704573)

  • 1. Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial.
    Hara A; Shimizu M; Hamaguchi E; Kakuda H; Ikeda K; Okumura T; Kitagawa K; Koshino Y; Kobayashi M; Takasawa K; Hisada Y; Toyama T; Iwata Y; Sakai N; Wada T
    Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00159. PubMed ID: 32704573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
    de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
    de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
    Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
    Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy.
    Gale JD; Gilbert S; Blumenthal S; Elliott T; Pergola PE; Goteti K; Scheele W; Perros-Huguet C
    Kidney Int Rep; 2018 Nov; 3(6):1316-1327. PubMed ID: 30450458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
    Heerspink HJL; Kiyosue A; Wheeler DC; Lin M; Wijkmark E; Carlson G; Mercier AK; Åstrand M; Ueckert S; Greasley PJ; Ambery P
    Lancet; 2023 Nov; 402(10416):2004-2017. PubMed ID: 37931629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
    Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
    Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
    Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
    Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
    Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.